Search details
1.
Novel endoscopic scoring system for immune mediated colitis: A Multicenter Retrospective Study of 674 Patients.
Gastrointest Endosc
; 2024 Jan 23.
Article
in English
| MEDLINE | ID: mdl-38272276
2.
IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience.
Am J Gastroenterol
; 118(9): 1679-1683, 2023 09 01.
Article
in English
| MEDLINE | ID: mdl-37216614
3.
Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy.
J Gastroenterol Hepatol
; 37(10): 1983-1990, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35730192
4.
Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor-Related Colitis in Patients with Cancer.
Cancers (Basel)
; 16(10)2024 May 18.
Article
in English
| MEDLINE | ID: mdl-38791997
5.
Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center.
Cancers (Basel)
; 16(2)2024 Jan 15.
Article
in English
| MEDLINE | ID: mdl-38254858
6.
Characteristics, treatment, and outcome of patients with bowel perforation after immune checkpoint inhibitor exposure.
J Cancer Res Clin Oncol
; 149(9): 5989-5998, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-36611109
7.
Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors.
J Cancer Res Clin Oncol
; 149(8): 5429-5436, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-36451045
8.
Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients.
J Cancer Res Clin Oncol
; 149(8): 4591-4599, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-36163559
9.
Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
J Cancer Res Clin Oncol
; 149(9): 6341-6350, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-36752908
10.
Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects.
J Cancer Res Clin Oncol
; 149(7): 3965-3976, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-36030431
11.
Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis.
Cancers (Basel)
; 15(8)2023 Apr 17.
Article
in English
| MEDLINE | ID: mdl-37190257
12.
Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment.
Am J Clin Oncol
; 46(8): 360-365, 2023 08 01.
Article
in English
| MEDLINE | ID: mdl-37219360
13.
Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity.
J Cancer Res Clin Oncol
; 149(10): 7793-7803, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37029815
14.
Sclerosing mesenteritis following immune checkpoint inhibitor therapy.
J Cancer Res Clin Oncol
; 149(11): 9221-9227, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37195298
15.
Clinical Features and Management of Acute and Chronic Radiation-Induced Colitis and Proctopathy.
Cancers (Basel)
; 15(12)2023 Jun 12.
Article
in English
| MEDLINE | ID: mdl-37370770
16.
Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor-mediated Colitis.
J Cancer
; 14(14): 2686-2693, 2023.
Article
in English
| MEDLINE | ID: mdl-37779873
17.
Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer.
J Cancer
; 14(10): 1913-1919, 2023.
Article
in English
| MEDLINE | ID: mdl-37476185
18.
The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review.
J Cancer
; 14(16): 2956-2963, 2023.
Article
in English
| MEDLINE | ID: mdl-37859810
19.
Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors.
J Cancer Res Clin Oncol
; 149(19): 17597-17605, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37917197
20.
Characteristics, treatment, and outcome of diverticulitis after immune checkpoint inhibitor treatment in patients with malignancies.
J Cancer Res Clin Oncol
; 149(8): 4805-4816, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-36242603